{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T01:25:30Z","timestamp":1777685130072,"version":"3.51.4"},"reference-count":22,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T00:00:00Z","timestamp":1566864000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JHD"],"published-print":{"date-parts":[[2019,8,27]]},"DOI":"10.3233\/jhd-199003","type":"journal-article","created":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T11:30:10Z","timestamp":1564486210000},"page":"363-371","source":"Crossref","is-referenced-by-count":35,"title":["Huntington\u2019s Disease Clinical Trials Corner: June 2019"],"prefix":"10.1177","volume":"8","author":[{"given":"Filipe B.","family":"Rodrigues","sequence":"first","affiliation":[{"name":"UCL Huntington\u2019s Disease Centre, UCL Queen Square Institute of Neurology, University College London, London, UK"},{"name":"Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal"},{"name":"Instituto de Medicina Molecular, Lisbon, Portugal"}]},{"given":"Joaquim J.","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal"},{"name":"Instituto de Medicina Molecular, Lisbon, Portugal"},{"name":"CNS - Campus Neurol\u00f3gico S\u00e9nior, Torres Vedras, Portugal"}]},{"given":"Edward J.","family":"Wild","sequence":"additional","affiliation":[{"name":"UCL Huntington\u2019s Disease Centre, UCL Queen Square Institute of Neurology, University College London, London, UK"}]}],"member":"179","reference":[{"issue":"3","key":"10.3233\/JHD-199003_ref3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3233\/JHD-170262","article-title":"Clinical trials corner: September 2017","volume":"6","author":"Rodrigues","year":"2017","journal-title":"J Huntingtons Dis"},{"key":"10.3233\/JHD-199003_ref4","doi-asserted-by":"crossref","unstructured":"Tabrizi SJ , Leavitt BR , Landwehrmeyer GB , Wild EJ , Saft C , Barker RA , et al. Targeting huntingtin expression in patients with huntington\u2019s disease. The New England Journal of Medicine. 2019.","DOI":"10.1056\/NEJMoa1900907"},{"issue":"3","key":"10.3233\/JHD-199003_ref11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/brainsci6030038","article-title":"Deep brain stimulation in huntington\u2019s disease-preliminary evidence on pathophysiology, efficacy and safety","volume":"6","author":"Wojtecki","year":"2016","journal-title":"Brain Sci"},{"key":"10.3233\/JHD-199003_ref12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fneur.2015.00177","article-title":"A prospective pilot trial for pallidal deep brain stimulation in huntington\u2019s disease","volume":"6","author":"Wojtecki","year":"2015","journal-title":"Front Neurol"},{"issue":"1","key":"10.3233\/JHD-199003_ref13","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3171\/2014.2.JNS131722","article-title":"Deep brain stimulation for Huntington\u2019s disease: Long-term results of a prospective open-label study","volume":"121","author":"Gonzalez","year":"2014","journal-title":"Journal of Neurosurgery"},{"issue":"11","key":"10.3233\/JHD-199003_ref14","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1002\/jnr.24111","article-title":"Triheptanoin for the treatment of brain energy deficit: A 14-year experience","volume":"95","author":"Mochel","year":"2017","journal-title":"Journal of Neuroscience Research"},{"issue":"2","key":"10.3233\/JHD-199003_ref15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3233\/JHD-170245","article-title":"Fifteen years of clinical trials in huntington\u2019s disease: A very low clinical drug development success rate","volume":"6","author":"Travessa","year":"2017","journal-title":"Journal of Huntington\u2019s Disease"},{"issue":"12","key":"10.3233\/JHD-199003_ref16","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1176\/ajp.152.12.1771","article-title":"Trial of d-alpha-tocopherol in Huntington\u2019s disease","volume":"152","author":"Peyser","year":"1995","journal-title":"Am J Psychiatry"},{"issue":"5","key":"10.3233\/JHD-199003_ref17","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/mds.870110510","article-title":"A controlled trial of idebenone in Huntington\u2019s disease","volume":"11","author":"Ranen","year":"1996","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"3","key":"10.3233\/JHD-199003_ref18","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1212\/WNL.57.3.397","article-title":"A randomized placebo-controlled trial of coenzyme Q10 and remacemide in Huntington\u2019s disease","volume":"57","author":"Huntington Study Group","year":"2001","journal-title":"Neurology"},{"issue":"2","key":"10.3233\/JHD-199003_ref19","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1212\/01.wnl.0000169025.09670.6d","article-title":"Ethyl-EPA in Huntington disease: A double-blind, randomized, placebo-controlled trial","volume":"65","author":"Puri","year":"2005","journal-title":"Neurology"},{"issue":"12","key":"10.3233\/JHD-199003_ref20","first-page":"1582","article-title":"Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: The TREND-HD study","volume":"65","author":"Dorsey","year":"2008","journal-title":"Archives of Neurology"},{"issue":"10","key":"10.3233\/JHD-199003_ref21","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/mds.26308","article-title":"Ethyl-eicosapentaenoic acid treatment in Huntington\u2019s disease: A placebo-controlled clinical trial","volume":"30","author":"Ferreira","year":"2015","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"10","key":"10.3233\/JHD-199003_ref22","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1212\/WNL.0000000000000187","article-title":"PRECREST: A phase II prevention and biomarker trial of creatine in at-risk Huntington disease","volume":"82","author":"Rosas","year":"2014","journal-title":"Neurology"},{"issue":"6","key":"10.3233\/JHD-199003_ref23","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1212\/WNL.0000000000004209","article-title":"The CREST-E study of creatine for Huntington disease: A randomized controlled trial","volume":"89","author":"Hersch","year":"2017","journal-title":"Neurology"},{"issue":"2","key":"10.3233\/JHD-199003_ref24","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/01.wnl.0000194318.74946.b6","article-title":"Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2\u2019dG","volume":"66","author":"Hersch","year":"2006","journal-title":"Neurology"},{"issue":"5","key":"10.3233\/JHD-199003_ref25","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1136\/jnnp-2015-311475","article-title":"Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency","volume":"87","author":"Mochel","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"10.3233\/JHD-199003_ref26","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/ejhg.2010.72","article-title":"Dietary anaplerotic therapy improves peripheral tissue energy metabolism in patients with Huntington\u2019s disease","volume":"18","author":"Mochel","year":"2010","journal-title":"European Journal of Human Genetics: EJHG"},{"issue":"5","key":"10.3233\/JHD-199003_ref27","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1212\/WNL.0000000000001214","article-title":"Triheptanoin improves brain energy metabolism in patients with Huntington disease","volume":"84","author":"Adanyeguh","year":"2015","journal-title":"Neurology"},{"issue":"1","key":"10.3233\/JHD-199003_ref28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3233\/JHD-189001","article-title":"Huntingtons disease clinical trials corner: February 2018","volume":"7","author":"Rodrigues","year":"2018","journal-title":"Journal of Huntington\u2019s Disease"},{"issue":"3","key":"10.3233\/JHD-199003_ref29","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3233\/JHD-189003","article-title":"Huntington\u2019s disease clinical trials corner: August 2018","volume":"7","author":"Rodrigues","year":"2018","journal-title":"J Huntingtons Dis"},{"issue":"1","key":"10.3233\/JHD-199003_ref30","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3233\/JHD-190001","article-title":"Huntington\u2019s disease clinical trials corner: January 2019","volume":"8","author":"Rodrigues","year":"2019","journal-title":"Journal of Huntington\u2019s Disease"}],"container-title":["Journal of Huntington's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JHD-199003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:50:51Z","timestamp":1777452651000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JHD-199003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,27]]},"references-count":22,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/jhd-199003","relation":{},"ISSN":["1879-6397","1879-6400"],"issn-type":[{"value":"1879-6397","type":"print"},{"value":"1879-6400","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,27]]}}}